Literature DB >> 15326083

Myocardial perfusion during long-term angiotensin-converting enzyme inhibition or beta-blockade in patients with essential hypertension.

Niels H Buus1, Morten Bøttcher, Claus G Jørgensen, Kent L Christensen, Kristian Thygesen, Torsten T Nielsen, Michael J Mulvany.   

Abstract

Hypertension is associated with reduced coronary vasodilatory capacity, possibly caused by structural changes in the coronary resistance vessels. Because vasodilatory treatment may correct abnormal structure better than nonvasodilating treatment, we compared whether long-term angiotensin-converting enzyme (ACE) inhibition has a greater effect on coronary reserve and cardiovascular structure than beta-blockade in patients with essential hypertension. Thirty previously untreated hypertensive patients were randomized in a double-blind design to treatment for 1 year with either perindopril (4 to 8 mg per day, n=15) or atenolol (50 to 100 mg per day, n=15) and furthermore compared with normotensive controls. Cardiac output and left ventricular mass were measured with echocardiography and resistance artery structure was determined in vitro. Using positron emission tomography, myocardial perfusion (MP) was determined at rest and during dipyridamole-induced hyperemia while still on medication. Perindopril reduced left ventricular mass by 14+/-4% (P<0.01), peripheral vascular resistance by 12+/-6% (P<0.01), and media thickness-to-lumen diameter ratio of resistance arteries by 16+/-4% (P<0.05), whereas atenolol had no effect. Resting MP was decreased both by perindopril (-11+/-4%, P<0.01) and by atenolol (-25+/-4%, P<0.01) in parallel to the reduction in rate pressure product. Hyperemic MP was unaltered by perindopril (+2+/-6%, P=NS), but reduced by atenolol (-32+/-5%, P<0.01). Compared with atenolol, perindopril treatment resulted in higher coronary reserve (P<0.05). We conclude that compared with beta-blockade, ACE inhibition increases coronary reserve and results in regression of hypertensive resistance artery structure and left ventricular hypertrophy. Vasodilating may thus be superior to nonvasodilating treatment in repairing the hypertensive myocardial microcirculation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15326083     DOI: 10.1161/01.HYP.0000141273.72768.b7

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  20 in total

1.  [11C]Acetate rest-stress protocol to assess myocardial perfusion and oxygen consumption reserve in a model of congestive heart failure in rats.

Authors:  Etienne Croteau; Suzanne Gascon; M'hamed Bentourkia; Réjean Langlois; Jacques A Rousseau; Roger Lecomte; François Bénard
Journal:  Nucl Med Biol       Date:  2011-11-12       Impact factor: 2.408

Review 2.  Small artery remodelling in hypertension: causes, consequences and therapeutic implications.

Authors:  Michael J Mulvany
Journal:  Med Biol Eng Comput       Date:  2008-05       Impact factor: 2.602

Review 3.  The vasodilatory beta-blockers.

Authors:  Michala E Pedersen; John R Cockcroft
Journal:  Curr Hypertens Rep       Date:  2007-08       Impact factor: 5.369

Review 4.  Coronary microvascular dysfunction: mechanisms and functional assessment.

Authors:  Paolo G Camici; Giulia d'Amati; Ornella Rimoldi
Journal:  Nat Rev Cardiol       Date:  2014-10-14       Impact factor: 32.419

5.  Influence of Renal Transplantation and Living Kidney Donation on Large Artery Stiffness and Peripheral Vascular Resistance.

Authors:  Niels H Buus; Rasmus K Carlsen; Alun D Hughes; Karin Skov
Journal:  Am J Hypertens       Date:  2020-03-13       Impact factor: 2.689

6.  Positive effects of aggressive vasodilator treatment of well-treated essential hypertensive patients.

Authors:  M Engholm; M J Mulvany; A Eftekhari; O N Mathiassen; N H Buus; K L Christensen
Journal:  J Hum Hypertens       Date:  2016-03-10       Impact factor: 3.012

Review 7.  Perindopril: a review of its use in patients with or at risk of developing coronary artery disease.

Authors:  Monique P Curran; Paul L McCormack; Dene Simpson
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 8.  Perindopril versus angiotensin II receptor blockade in hypertension and coronary artery disease: implications of clinical trials.

Authors:  Adrian J B Brady
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

9.  Blood pressure normalization via pharmacotherapy improves cutaneous microvascular function through NO-dependent and NO-independent mechanisms.

Authors:  Daniel H Craighead; Caroline J Smith; Lacy M Alexander
Journal:  Microcirculation       Date:  2017-10       Impact factor: 2.628

10.  Relation of left ventricular mass and concentric remodeling to extent of coronary artery disease by computed tomography in patients without left ventricular hypertrophy: ROMICAT study.

Authors:  Quynh A Truong; Michael Toepker; Amir A Mahabadi; Fabian Bamberg; Ian S Rogers; Ron Blankstein; Thomas J Brady; John T Nagurney; Udo Hoffmann
Journal:  J Hypertens       Date:  2009-12       Impact factor: 4.844

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.